FDA approves first epoetin alfa biosimilar for the treatment of anemia
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
More News: Anemia | Chemotherapy | Chronic Kidney Disease | Epogen | Food and Drug Administration (FDA) | Pharmaceuticals | Procrit | Urology & Nephrology